Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

  • Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19
  • MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage
  • Switzerland based Molecular Partners, a global leader in the development of DARPin …
/by